Get the app
US › Healthcare

Zura Bio Limited Class A Ordinary Shares (ZURA)

US · Healthcare · Biotechnology

$3.88-9.35%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-26.3M
EPS
$-0.21
EPS estimate
$-0.20

EPS came in at -0.21 against a street estimate of -0.20 — a miss of 5.0%.

Key statistics

Market cap
$383.3M
Forward P/E
0.0
P/B
2.10
Book value
$2.06
EPS (TTM)
$-1.12
52-week high
$7.44
52-week low
$3.15
50-day MA
$5.17
200-day MA
$5.32
Beta
0.01

Analyst view

Analysts rate Zura Bio Limited Class A Ordinary Shares a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $18.00.

Shareholding

Insiders
18.92%
Institutions
87.87%

Largest institutional holders

FundStake
Suvretta Capital Management, LLC9.85%
VR Adviser, LLC6.72%
MPM Oncology Impact Management LP4.67%
JPMorgan Chase & Co4.54%
Great Point Partners LLC4.40%
BRAIDWELL LP4.15%
Siren, L.L.C.3.90%
BlackRock Inc3.77%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Zura Bio Limited Class A Ordinary Shares — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.